12 results
8-K
EX-99.1
SYRA
Syra Health Corp. Class A Common Stock
9 Aug 24
Results of Operations and Financial Condition
4:05pm
office equipment. R&D expenses were $277,548, reflecting the development of technology-based solutions.
Net Loss for the second quarter of 2024 was $(1.4
8-K
EX-99.1
SYRA
Syra Health Corp. Class A Common Stock
9 May 24
Results of Operations and Financial Condition
5:17pm
compared to $11,763 in the first quarter of 2023, reflecting expanded office space. R&D expenses were $277,548, reflecting the development of technology
DEF 14A
SYRA
Syra Health Corp. Class A Common Stock
24 Apr 24
Definitive proxy
5:01pm
including R&D Innovation Incubator Leader from January 2015 to December 2017; Competitive Intelligence Leader from January 2009 to December 2017
8-K
EX-99.1
SYRA
Syra Health Corp. Class A Common Stock
25 Mar 24
Results of Operations and Financial Condition
4:30pm
office space. R&D expenses were $240,048, reflecting the development of technology-based solutions.
Net Loss for 2023 was $(2.94 million) compared
8-K
SYRA
Syra Health Corp. Class A Common Stock
4 Oct 23
Syra Health Corp. Announces Pricing of Upsized Initial Public Offering
4:45pm
and seed company and spin-off from Dow-DuPont. Dr. Reddy joined Dow AgroSciences in January 1999 and served in various roles including R&D Innovation
424B4
oavnsxt
3 Oct 23
Prospectus supplement with pricing info
6:10am
S-1/A
rzu12 qc1dws
12 Jun 23
IPO registration (amended)
9:05pm
S-1
80vqq3fd
3 May 23
IPO registration
9:34pm
- Prev
- 1
- Next